Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinomaReportar como inadecuado




Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Cancer

, 11:42

Translational oncology

Abstract

BackgroundThe SRY-related HMG-box family of transcription factors member SOX2 has been mainly studied in embryonic stem cells as well as early foregut and neural development. More recently, SOX2 was shown to participate in reprogramming of adult somatic cells to a pluripotent stem cell state and implicated in tumorigenesis in various organs. In breast cancer, SOX2 expression was reported as a feature of basal-like tumors. In this study, we assessed SOX2 expression in 95 primary tumors of postmenopausal breast cancer patients.

MethodsSamples from 95 patients diagnosed and treated at the University of Tuebingen Institute of Pathology and Women-s Hospital were analyzed by immunohistochemistry for SOX2 expression in the primary tumor samples and in corresponding lymph node metastasis, where present. Furthermore, SOX2 amplification status was assessed by FISH in representative samples. In addition, eighteen fresh frozen samples were analyzed for SOX2, NANOG and OCT4 gene expression by real-time PCR.

ResultsSOX2 expression was detected in 28% of invasive breast carcinoma as well as in 44% of ductal carcinoma in situ DCIS lesions. A score of SOX2 expression score 0 to 3 was defined in order to distinguish SOX2 negative score 0 from SOX2 positive samples score 1-3 and among latter the subgroup of SOX2 high expressors score 3 > 50% positive cells. Overall, the incidence of SOX2 expression score 1-3 was higher than previously reported in a cohort of lymph node negative patients 28% versus 16.7%. SOX2 expression was detected across different breast cancer subtypes and did not correlate with tumor grading. However, high SOX2 expression score 3 was associated with larger tumor size p = 0.047 and positive lymph node status 0.018. Corresponding metastatic lymph nodes showed higher SOX2 expression and were significantly more often SOX2 positive than primary tumors p = 0.0432.

ConclusionsIn this report, we show that the embryonic stem cell factor SOX2 is expressed in a variety of early stage postmenopausal breast carcinomas and metastatic lymph nodes. Our data suggest that SOX2 plays an early role in breast carcinogenesis and high expression may promote metastatic potential. Further studies are needed to explore whether SOX2 can predict metastatic potential at an early tumor stage.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2407-11-42 contains supplementary material, which is available to authorized users.

Claudia Lengerke, Tanja Fehm, Ralf Kurth, Petra M Bareiss and Annette Staebler contributed equally to this work.

Download fulltext PDF



Autor: Claudia Lengerke - Tanja Fehm - Ralf Kurth - Hans Neubauer - Veit Scheble - Friederike Müller - Friederike Schneider - Kar

Fuente: https://link.springer.com/







Documentos relacionados